Early data from ARCT-032 trial for CF expected next month

Early data from ARCT-032 trial for CF expected next month

Interim results from the first nine participants in a Phase 2 clinical trial testing Arcturus Therapeutics’ experimental inhaled therapy ARCT-032 in adults with cystic fibrosis (CF) are expected next month. The U.S.-based study, called LunairCF (NCT06747858), is still recruiting CF patients who aren’t eligible for CFTR modulators or who have been off these standard treatments for at least 60 days. The trial’s enrollment, which has a target of 12…